Repligen (NASDAQ:RGEN) Now Covered by Analysts at UBS Group

UBS Group assumed coverage on shares of Repligen (NASDAQ:RGEN) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $225.00 price target on the biotechnology company’s stock. UBS Group’s price objective points to a potential upside of 34.63% from the stock’s current price.

Several other research analysts have also weighed in on the stock. Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. increased their price target on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Wells Fargo & Company lifted their price target on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 13th. Finally, Evercore reissued an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a report on Monday, July 6th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $168.57.

Repligen Stock Down 0.8%

Shares of Repligen stock traded down $1.40 on Wednesday, hitting $167.13. 35,404 shares of the company’s stock traded hands, compared to its average volume of 1,012,732. Repligen has a 52-week low of $100.99 and a 52-week high of $188.73. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.43 billion, a P/E ratio of 228.76, a PEG ratio of 3.06 and a beta of 1.05. The firm’s 50-day moving average is $156.80 and its 200 day moving average is $134.68.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts anticipate that Repligen will post 2.06 earnings per share for the current year.

Insider Activity

In other news, CFO Jason Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently modified their holdings of RGEN. ABS Investment Management LLC bought a new position in shares of Repligen during the second quarter valued at approximately $191,016,000. Measured Wealth Private Client Group LLC bought a new position in Repligen during the 3rd quarter worth $29,000. Los Angeles Capital Management LLC acquired a new stake in Repligen in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. lifted its stake in Repligen by 38.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 104 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of Repligen during the second quarter valued at $52,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.